Thyroid risk with GLP-1 is a regular concern. Here’s what human versus animal data indicate.
The FDA’s black box warning regarding the risk of C-cell thyroid tumors with GLP-1 agonists has generated understandable concern among patients. This warning is based on animal data. What is the actual situation in humans?
The Origin of the Warning: Animal Data
Preclinical studies in rats have shown a dose-dependent increase in C-cell thyroid tumors (medullary thyroid carcinoma, MTC) with GLP-1 agonists. These tumors are linked to the activation of GLP-1 receptors present on the parafollicular C-cells of the thyroid in rats. However, the density of GLP-1 receptors on thyroid C-cells is significantly lower in humans than in rodents, which limits the translatability of these results.
Human Data
Pharmacovigilance data accumulated over more than 15 years of GLP-1 agonist use (since exenatide in 2005) are reassuring. Meta-analyses including millions of patient-years of exposure show no significant increase in the risk of MTC in humans. The LEADER study (liraglutide) and combined data from the SURPASS and SURMOUNT programs report no excessive cases of thyroid tumors.
A Danish cohort study (2024) involving over 100,000 patients treated with GLP-1 agonists for more than 5 years found no signal of increased MTC risk. The thyroid cancer rate in this population was identical to that of the general population.
Precautions and Contraindications
- Absolute contraindication: personal or family history of medullary thyroid carcinoma (MTC)
- Absolute contraindication: Multiple Endocrine Neoplasia type 2 syndrome (MEN2)
- Monitoring: Calcitonin measurement not routinely recommended but should be discussed in case of risk factors
- Warning signs: palpable thyroid nodule, dysphagia, dysphonia, cervical lymphadenopathy — consult promptly
Position of Scientific Societies
The Endocrine Society, the ATA (American Thyroid Association), and the EASD do not recommend routine MTC screening before or during GLP-1 agonist treatment, in the absence of specific risk factors. The benefit-risk ratio is considered very favorable in the treatment of obesity and diabetes.
Track your progress with the MounjaGO app.
FAQ
Can Mounjaro cause thyroid cancer?
Human data from over 15 years of GLP-1 use show no significant increased risk. The warning is based on non-translatable animal data. Nevertheless, Mounjaro is contraindicated in cases of a history of medullary carcinoma.
Is a thyroid ultrasound necessary before starting Mounjaro?
No, unless there is a personal or family history of thyroid disease, a palpable nodule, or suggestive symptoms. TSH measurement is recommended to screen for hypothyroidism.
Is calcitonin measurement necessary with Mounjaro?
It is not routinely recommended. It may be suggested in cases of specific risk factors for medullary carcinoma, upon endocrinological advice.